UMR DIATHEC, EA 7294, Centre Européen d'Etude du Diabète, Université de Strasbourg (UdS), Boulevard René Leriche, 67200 Strasbourg, France.
Institut Charles Sadron (UPR 22 CNRS), 23 rue du Loess, BP 84047 67034 Strasbourg Cedex 2, France.
Int J Pharm. 2018 May 5;542(1-2):47-55. doi: 10.1016/j.ijpharm.2018.02.045. Epub 2018 Mar 6.
Oral administration of insulin increases patient comfort and could improve glycemic control thanks to the hepatic first passage. However, challenges remain. The current approach uses poly (d, lactic-co-glycolic) acid (PLGA) nanoparticles (NPs), an effective drug carrier system with a long acting profile. However, this system presents a bioavailability of less than 20% for insulin encapsulation. In this context, physico-chemical parameters like surface charge could play a critical role in NP uptake by the intestinal barrier. Therefore, we developed a simple method to modulate NP surface charge to test its impact on uptake in vitro and finally on NP efficiency in vivo. Various NPs were prepared in the presence (+) or absence (-) of polyvinyl alcohol (PVA), sodium dodecyl sulfate (SDS), and/or coated with chitosan chloride. In vitro internalization was tested using epithelial culture of Caco-2 or using a co-culture (Caco-2/RevHT29MTX) by flow cytometry. NPs were then administered by oral route using a pharmaceutical complex vector (100 or 250 UI/kg) in a diabetic rat model. SDS-NPs (-42 ± 2 mV) were more negatively charged than -PVA-NPs (-22 ± 1 mV) and chitosan-coated NPs were highly positively charged (56 ± 2 mV) compared to +PVA particles (-2 ± 1 mV), which were uncharged. In the Caco-2 model, NP internalization was significantly improved by using negatively charged NPs (SDS NPs) compared to using classical NPs (+PVA NPs) and chitosan-coated NPs. Finally, the efficacy of insulin SDS-NPs was demonstrated in vivo (100 or 250 UI insulin/kg) with a reduction of blood glucose levels in diabetic rats. Formulation of negatively charged NPs represents a promising approach to improve NP uptake and insulin bioavailability for oral delivery.
口服给予胰岛素可以增加患者的舒适度,并通过肝脏首过效应改善血糖控制。然而,仍然存在挑战。目前的方法使用聚(D,L-丙交酯-共-乙交酯)酸(PLGA)纳米颗粒(NPs),这是一种具有长效特征的有效药物载体系统。然而,这种系统对于胰岛素包封的生物利用度低于 20%。在这种情况下,物理化学参数,如表面电荷,可能在 NP 被肠道屏障摄取中发挥关键作用。因此,我们开发了一种简单的方法来调节 NP 的表面电荷,以测试其对体外摄取的影响,最终对体内 NP 的效率产生影响。通过在存在(+)或不存在(-)聚乙烯醇(PVA)、十二烷基硫酸钠(SDS)和/或壳聚糖氯化物的情况下制备各种 NPs。通过流式细胞术测试上皮细胞培养的 Caco-2 或使用共培养(Caco-2/RevHT29MTX)的细胞内化。然后通过口服途径使用药物复合载体(100 或 250 UI/kg)在糖尿病大鼠模型中给予 NPs。与-PVA-NPs(-22±1 mV)相比,SDS-NPs(-42±2 mV)带更多负电荷,与带正电荷的壳聚糖涂层 NPs(56±2 mV)相比,+PVA 颗粒(-2±1 mV)带更少正电荷。在 Caco-2 模型中,与使用经典 NPs(+PVA NPs)和壳聚糖涂层 NPs 相比,使用带负电荷的 NPs(SDS NPs)显著提高了 NP 的内化。最后,体内证实了胰岛素 SDS-NPs 的疗效(100 或 250 UI 胰岛素/kg),糖尿病大鼠的血糖水平降低。负电荷 NPs 的配方代表了一种有前途的方法,可以提高 NP 摄取和口服递送的胰岛素生物利用度。